Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02.

ABSTRACT: Novel treatments for glioblastoma, the most common malignant primary brain tumor, are urgently required. Type I interferons (IFN) are natural cytokines primarily involved in the defense against viral infections, which may also serve a role in the control of cancer, notably in the suppression of the cancer stem cell phenotype. TG02 is a novel orally available cyclin-dependent kinase 9 inhibitor which induces glioma cell apoptosis without profound caspase activation, which is currently explored in early clinical trials in newly diagnosed and recurrent glioblastoma. In the present study, human glioma-initiating cell line models were used to explore whether IFN-β modulates the anti-glioma activity of TG02. The present study employed immunoblotting to assess protein levels, several viability as

SUBMITTER: Lohmann B 

PROVIDER: S-EPMC7068396 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature